Northern Trust Corp Buys 243,522 Shares of Standard BioTools Inc. (NASDAQ:LAB)

Northern Trust Corp boosted its position in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 9.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,875,160 shares of the company's stock after buying an additional 243,522 shares during the period. Northern Trust Corp owned approximately 0.77% of Standard BioTools worth $5,032,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Aquatic Capital Management LLC acquired a new position in shares of Standard BioTools during the fourth quarter valued at about $45,000. Two Sigma Securities LLC acquired a new position in shares of Standard BioTools during the fourth quarter valued at about $30,000. Evercore Wealth Management LLC acquired a new position in shares of Standard BioTools during the fourth quarter valued at about $219,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Standard BioTools by 10.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 181,468 shares of the company's stock valued at $318,000 after purchasing an additional 16,475 shares during the period. Finally, Mirabella Financial Services LLP acquired a new position in shares of Standard BioTools during the fourth quarter valued at about $5,478,000. Institutional investors and hedge funds own 53.74% of the company's stock.

Standard BioTools Trading Down 3.4%

Shares of LAB traded down $0.03 on Friday, reaching $0.92. The company's stock had a trading volume of 2,591,697 shares, compared to its average volume of 2,138,278. Standard BioTools Inc. has a twelve month low of $0.92 and a twelve month high of $2.65. The stock has a market capitalization of $350.04 million, a PE ratio of -1.30 and a beta of 1.80. The firm has a fifty day moving average of $1.12 and a 200-day moving average of $1.45.

Insider Buying and Selling

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average price of $1.06 per share, for a total transaction of $5,110,216.54. Following the acquisition, the director now directly owns 58,846,780 shares of the company's stock, valued at approximately $62,377,586.80. The trade was a 8.92% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 31,500 shares of company stock worth $32,069 in the last quarter. Insiders own 23.16% of the company's stock.

Analysts Set New Price Targets

Separately, KeyCorp lowered shares of Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.